Tag: DBV Technologies

Viaskin-Patch

FDA Removes Hold Allowing DBV’s Pivotal Phase 3 Peanut Patch Trial...

The phase 3 trial of the modified Viaskin Peanut patch has been cleared for commencement.
Viaskin Patch

Skin Patch Immunotherapy Determined Safe and Effective in Toddlers With Peanut...

According to research presented at this year's #ACAAI22 meeting.
Viaskin Peanut

Private Law Firm to Investigate Claims on Behalf of Investors in...

It is unknown how this development will affect the ability of the company to eventually offer Viaskin Peanut as an FDA approved therapy.
Viaskin Peanut

FDA Issues Partial Hold on DBV Viaskin Peanut Patch Trial

Another delay for the long-awaited therapy.
Viaskin Patch

DBV Begins Phase 3 Study of Redesigned Viaskin Peanut Patch in...

Viaskin is testing a new version of their patch designed to address the FDA's concerns.
Viaskin Patch

DBV Announces Positive Topline Results from Phase 3 Trial of Viaskin...

Viaskin Peanut demonstrated a statistically significant treatment effect with 67.0% of subjects meeting the treatment responder criteria after 12 months.
Viaskin-Patch

Safety of Viaskin Peanut Patch Therapy Improved Over 3-Year Study

Reactions decreased over study duration.
Viaskin Peanut

FDA Wants More Viaskin Peanut Data Resulting in Further Approval Delays

Delays mount pushing trials of modified patch.
Moonlight Therapeutics Microneedle Patch

New Microneedle Patch Therapy for Food Allergies Takes Step Forward

Painless microneedle patch may provide new method for desensitization.
Viaskin Patch

DBV Optimistic Viaskin Peanut “Patch” Therapy has Path to Approval After...

DBV, which also has Viaskin therapies for milk and egg allergies in their pipeline, is encouraged by FDA feedback after denial of their peanut therapy.